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Summary 
The relationship between primary and memory cytotoxic T  lymphocyte (CTL) responses, and 
the factors influencing entry into memory, are poorly understood.  Here we address this in the 
context  of Epstein-Barr  virus  (EBV),  a persistent  human  herpesvirus  in which  memory CTL 
responses in long-term virus careers are highly focused on epitopes preferentially drawn from 
just  three  of the  eight  available virus latent proteins,  EBNAs  3A,  3B,  and  3C.  To detem-fine 
whether this unusual  level of focusing is a consequence  of long-term virus challenge,  we car- 
ried out  a  detailed  analysis of EBV antigen/epitope  specificities in the  primary virus-induced 
CTL  response  in  10  infectious  mononucleosis  (IM)  patients  of different  HLA types.  Primary 
effectors, studied in ex vivo assays and by limiting dilution  cloning in vitro, were again highly 
skewed toward a small number of viral epitopes, almost all derived from the EBNA3 proteins, 
with CTL to the immunodominant  epitope accounting for at least 1% of the circulating CD8 + 
IM T  cell pool. This is the first unequivocal demonstration of an EBV-specific CD8 + CTL re- 
sponse in  IM. Prospective studies  on individual  patients showed that,  whereas  all of the EBV 
reactivlties  found  in  CTL  memory had been  detectable  earlier  during  primary infection,  the 
memory population was not simply a scaled down version of the primary response. In particu- 
lar (a) differences in the relative frequencies  of CTL to imanunodominant  versus subdominant 
epitopes appeared to be much less marked in memory than in primary populations,  and  (b) we 
found at least one clear example in which a significant virus-specific reactivity within the pri- 
mary response was never detectable in memory. 
T 
he principal role ofCD8 + CTL is the immune control 
of  intracellular  pathogens,  in  particular  viruses  (1). 
Studies  in mouse  model systems have shown  that primary 
virus infection  can induce  the  activation  and rapid expan- 
sion  of CTL,  which  are virus specific and which  in many 
cases  are  capable  of clearing  the  infection  from  the  body 
(1-4). Though most of these primary effectors are then lost 
through  apoptosis  or  other  mechanisms  (5),  a  fraction  are 
selected  into  longer  term  memory  and  are  maintained 
thereafter,  apparently even in the  absence of cognate anti- 
gen  (6,  7).  The  precise  relationship  between  primary  and 
memory T  cell populations,  and the factors that determine 
selection  into  memory,  are  still  not  understood  (8,  9). 
These issues are especially interesting  for viruses that elicit 
strong CTL responses during primary infection but that are 
nevertheless  able to  persist in vivo  (10);  such  viruses pro- 
vide a continual  antigenic stimulus that might be expected 
to magnify the  effects of any selective recruitment  of par- 
tlcular  T  cell reactivities into  memory. EBV,  a  genetically 
stable herpesvlrus widespread in human populations,  is one 
such agent (11). 
Primary  infection  with  EBV,  as witnessed  in  infectious 
mononucleosis  (IM) 1, is characterized by rapid virus-driven 
expansion of a pool of latently infected B  cells followed by 
a  vigorous,  but  as  yet poorly  characterized,  CD8 +  T  cell 
response. During convalescence the number of latently in- 
fected cells in the B cell pool falls to a low steady state level, 
which is maintained thereafter for life (11). Most virus car- 
tiers,  irrespective  of HLA type,  possess  memory  CTL  re- 
sponses that are preferentially directed against members of a 
particular  subset  of EBV  latent  proteins,  namely,  the  nu- 
clear  antigens  EBNAs  3A,  3B,  and  3C.  The  other  latent 
cycle antigens  are  either seen  occasionally as  subdominant 
targets (e.g., EBNA2, EBNA-LP, and the latent membrane 
proteins  LMP  1  and  2)  or,  in  the  case of EBNA1,  appar- 
ently never recognized (12,  13). This marked degree of an- 
tigen immunodommance is further accentuated at the epitope 
level; thus, in any one individual,  the EBV-induced  mem- 
ory response tends to be dominated by reactivities to a very 
1Abbreviations used m this paper: IM, infectious mononucleosis; LCL, tym- 
phoblastmd cell hne; LMP, latent membrane protein. 
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stricted through just one or two of the available HLA class I 
alleles (14).  For example, in HLA-B8-positive individuals 
CTL memory to latent cycle antigens is very often domi- 
nated  by  clones  reactive  to  two  B8-restricted  epitopes, 
EBNA3A 325-333  and  158-166  (15,  16),  and in HLA- 
All-positive individuals by clones reactive to two All- 
restricted epitopes, EBNA3B 416-424 and 399-408 (17). 
The  relationship  between  this  extremely  focused  re- 
sponse seen in long-term virus carriers and the situation in 
primary EBV infection has never been analyzed at the level 
of antigen or epttope  choice.  Indeed the whole nature of 
the exaggerated CD8 + T  cell response in acute IM (18)  has 
remained controversial ever since these  circulating CD8 + 
effectors, depleted of CD16 + NK cells, were tested imme- 
diately ex vivo and found to display broad-ranging, appar- 
ently HLA-unrestricted, target  cell lysis  (19).  Subsequent 
work showed that, as in other instances of primary virus in- 
fection (4),  the in vivo activated CD8 + population in IM 
was functionally heterogeneous (20, 21) but, from the evi- 
dence of cold target competition assays,  appeared to  con- 
tain a vires-specific, HLA class I-restricted component (20). 
Here we present the first detailed analysis of EBV-specific 
effectors  within the  primary  CTL  response  and  compare 
the spectrum of primary reactivities with that subsequently 
detectable in T  cell memory. 
Materials and Methods 
Preparation oflM Effectors.  Blood samples (50 ml) were taken 
from  heterophile  antibody-posinve IM  patients  in  the  acute 
phase of the disease (4-14 d after onset) and then again 6-24 mo 
later,  long after  the disease symptoms  had resolved.  All patients 
were typed for HLA class I alleles by standard serological methods 
and, where necessary, by DNA typing (Dr. M. Hathaway,  Uni- 
versity of Birmingham). Mononuclear cells were prepared as de- 
scribed  (20) and cryopreserved  either immediately or,  in some 
cases, after  CD16 + NK cell depletion by treatment with IgG1 
mAb to CD16 (0813; Inmmnotech S.A., Marseille,  France) and 
rat anti-mouse IgG1 microbeads  (Miltenyi Biotec, Bergasch Glad- 
bach, Germany) according to manufacturers' instructions; in such 
cases, CD16 + cells were reduced from 5 to  16% to <1% of the 
mononuclear population.  Cryopreserved  cells were  thawed  in 
IL-2-supplemented  medium and, for ex vivo assays, used as effec- 
tors within 2 h. 
Stimulator~Target Cells.  Lymphoblastoid cell lines (LCL) car- 
rying either B95.8  EBV  (22) or the patient's endogenous EBV 
strain  were  generated by seeding mononuclear cells m  cyclo- 
sponn A  supplemented  (0.1 I.Lg/ml) standard  culture  medium 
(RPMI 1640, 2 mM glutamme, 100 IU/ml penicillin, 100 ~tg/ml 
streptomycin,  10%  vol/vol FCS),  respectively  with or without 
addition of a B95.8 virus preparation  (20). PHA-activated T-blasts 
(PHA blasts) were prepared by culturing mononuclear cells in the 
presence  of PHA (20 b~g/ml) and were thereafter  maintained in 
standard  culture medium supplemented with l% vol/vol pooled 
human serum and 30% vol/vol supernatant from the IL-2-pro- 
ducing cell line MLA  144  (MLA-SN). Fibroblast  cultures  were 
established from small skin biopsies from healthy donors and were 
maintamed in DME-based (rather  than RPMI  1640-based)  cul- 
ture medium. 
CTL Culture.  All in vitro work with primary CTL involved 
standard  culture medium supplemented with 1% vol/vol pooled 
human serum, 30% vol/vol MLA-SN, and 50 U/nil rIL2 (Proleu- 
kin, Eurocetus, Middlesex, UK).  Polyclonal T  cell lines were es- 
tablished by stimulating thawed mononuclear cells at 106/ml with 
the ",/-irradiated autologous LCL at a responder/stimulator ratio 
of 4:1 and were maintained thereafter  by twice weekly refeeding 
and by weekly LCL restimulation. Ohgoclones and clones were 
estabhshed  by seeding either the  thawed ex vivo mononuclear 
cell population at 0.3-300 cells/well or early passage polyclonal T 
cell lines at 0.3-3 cells/well,  in each case into 0.2-ml round-bot- 
tomed wells with 104 autologous LCL  cells/well and 105 feeder 
cells/well.  These  oligoclonal lines and clones were  further ex- 
panded by transfer to 2-ml wells with 10  s LCL cells/well and 106 
feeder cells/well.  The feeder cells were mononuclear  preparations 
from pooled fresh buffy coats (National Blood Service, Birming- 
ham, UK), which had been exposed to PHA at 10 btg/ml for 1 h 
and then washed  five times and cultured overnight. Feeder cells 
and  LCL  stimulators  were  always  irradiated  before  use.  The 
CD4/CD8 status ofpnmary CTL cultures was determined by in- 
&rect  lmmunofluorescence staining with  either  an  ann-CD4 
mAb (716; Dakopalts,  Glostrup,  Denmark) or an anti-CD8 mAb 
(707; Dakopalts, Glostrup, Denmark)  followed by goat anti-mouse 
IgG FITC (F0357; Sigma Chemical Co., St. Lores, MO). Poly- 
clonal memory CTL lines were established from fresh or cryopre- 
served mononuclear cells ofpostconvalescent  patients and subjected 
to limiting dilution cloning on day 14, as described  (23, 24). 
Cytotoxicity Assays.  All target  cells were labeled with SlCrO4 
for 2 h immediately before Incubation with effectors for 5-7 h in 
a standard  chromium release assay at known E/T ratios.  In re- 
combinant vacclnla assays, the  target  cells had  earlier  been ex- 
posed to the relevant vaccinia/EBV (1395.8) latent gene recombi- 
hints (12) for 2 h at a multiplicity of infection of 10:1 and then 
cultured for a further 14 h before labeling and use m a cytotoxlc- 
ity assay. For peptide sensitization  assays, peptides  were synthe- 
sized  by fluorenylmethoxycarbonyl chemistry  (Alta Bioscience, 
University of Birmingham, UK), &ssolved In DMSO and their 
concentration  was determined by a modified bIuret assay. Labeled 
PHA blast targets  (80 p,1) were first briefly incubated with dilu- 
nons of peptide (20 I*l) or with dilutions of DMSO solvent as a 
control in culture medium in 96 V-well assay plates, and then ef- 
fectors (100 ILl) were added for the subsequent 5-7 h incubation; 
the concentration of peptide quoted refers to that present in the 
final assay volume (200 ILl). Initial screening of sets of overlapping 
peptides for the identification of new epitopes was carried out us- 
ing a direct visual assay (25). 
Limiting Dilution Assays.  To  estimate  epitope-speclfic  CTL 
frequencies, mononuclear cells  were  seeded  across  a  range of 
input numbers in 0.2-ml round-bottomed wells  (24  replicates/ 
seeding) with 104 irradiated  autologous LCL cells and 10  s irradi- 
ated  feeders/well  in medium supplemented with  30%  vol/vol 
MLA-SN and 50 U/ml rlL-2; wells were refed at 5 d, and the as- 
say was camed out at 14 d, when each well was split four ways. 
Labeled  autologous PHA  blast  targets  were  incubated in bulk 
with peptides  representing appropriate  epltopes  or with DMSO 
at a similar concentration (no-peptide control) and then added to 
the above effectors, and the assay was harvested  after 5 h. Mean 
spontaneous release  was  calculated  for  each  target  cell/peptlde 
combination from  24  wells  containing no  effectors,  and mean 
maximum lysis was calculated  from between 6 and  12 replicate 
wells  of SDS-treated targets.  Wells were  scored  as  positive  for 
CTL recognition only If the level of specific lysis of the epatope- 
loaded  target  exceeded  10%  (this  threshold was  always  >3SD 
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Figure 1.  Screening of IM primary effectors lrmnedxately ex vxvo an 
cytotoxlcity assays. (Left)  Antigen-specific reactlvltles were detected using 
as targets either HLA class I-matched fibroblasts  or autologous spontane- 
ous LCL cells after their infection wtth recombinant vaccmla viruses ex- 
pressing lndwldual EBV latent proteins (EBNAs 1, 2, 3A, 3B, 3C, -LP 
and LMPs 1, 2) or umnt~cted cells as a control. (Right) Epltope-speclfic 
reactlwtles were detected using the autologous spontaneous LCL as a ref- 
erence  target  and  autologous PHA blasts preexposed to  the  denoted 
epltope pepudes at 2 Ixg/ml (A and C) or 0 2 I.tg/ml (B) or to an equiva- 
lent  dilution  of DMSO  solvent (no-peptlde  control).  Results are ex- 
pressed as percentage of specific  lysls  in 5-7-h chronuum release assays  for 
(A) IM59 effectors, (B) IM52 effectors tested at E/T ratxos of 80:1 (I) 
and 40:1 ([]), and (C) IM53 effectors tested at E/T ratios of 60:1 (11) and 
30.1 ([]). 
above the mean spontaneous release from the epitope-loaded tar- 
get) and also exceeded lysis of the no-peptide control target by at 
least 10%  (wells where lysls of the no-pepnde control was itself 
>15% were excluded from the analysis).  Frequency values were 
determined with 95% confidence limits from the cell input num- 
ber at which 37%  of the wells were negative for recogmtion of 
the target epitope, as calculated using the method of maximum 
likelihood (26); single hit kinetics were demonstrated by X  2 analysis. 
Results 
EB V Antigen/Epitope-specific Assays  Using Ex  Vivo IM Ef- 
fectors.  To look for evidence of EBV antigen- and epitope- 
specific reactivities in  IM effector preparations directly ex 
vivo, we  first selected IM patients with  at least one  HLA 
class  I  allele  for  which  CTL  epltopes  had  already  been 
idenufied from work with memory donors. Representative 
data from three such patients, IM59,  IM52,  and IM53,  are 
shown  in  Fig.  1.  Primary  ex  vivo  effectors  from  IM59 
(HLA-A1, A2,  B8,  B62)  were  assayed first  on  HLA-A2, 
B8-matched  fibroblast targets,  each  expressing one  of the 
EBV  latent proteins  (EBNAs  1,  2,  3A,  3B,  3C,  -LP,  and 
LMPs  1,  2) individually from a recombinant vaccinia virus 
vector. Specific lysis ofvacc-EBNA3A-infected target cells 
was  observed clearly above  the  background  levels shown 
by all the other targets (Fig.  1 A); this same result was ob- 
tained in three successive assays using thawed IM59 effec- 
tors  with  or  without  CD16 +  cell  depletion  (data  not 
shown). It is known from work with memory CTL prepa- 
rations  (15,  16)  that EBNA3A  contains  one  A2-restricted 
epitope (amino acids 596--604) and two BS-restricted epitopes 
(amino acids  158-166  and 325-333).  These same effectors 
were  therefore  screened  against  autologous  lymphoblasts 
preincubated with  synthetic peptides representing each of 
these epitopes and also two  known A2-restricted memory 
epitopes in another latent protein LMP2  (27, 28). We con- 
sistently observed strong  recognition  of both  of these  B8 
epitopes from EBNA3A but not of any of the A2-restricted 
epitopes (Fig.  1 A); note  that  the low-level reactivity ap- 
parent  against LMP2  426-434  in  this particular assay was 
not reproducible in repeat assays and also was  not  detect- 
able in subsequent clonal analysis. 
Primary  ex  vivo  effectors  from  a  second  donor,  IM52 
(HLA-A11,  A30,  B13,  B35),  were  likewise  assayed  on 
HLA-All,  B35-matched fibroblasts infected with the vac- 
cinia/EBV latent gene recombinants and reproducibly showed 
significant lysis of EBNA3B-positlve target cells (Fig. 1 B). 
Because A11-restricted memory CTL responses tend to fo- 
cus on two epitopes in EBNA3B, amino acids 399-408  and 
416-424  (17),  the  IM52  effectors were  therefore screened 
against these two peptides and also against a  third peptide, 
EBNA3A armno acids 458-466, known to be a preferred tar- 
get for memory CTL responses restricted through HLA-B35 
(16).  These  ex  vivo  assays revealed strong  recognition of 
one of these peptides, the All-restricted epitope EBNA3B 
416-424  (Fig. 1 B). Further assays on recombinant vaccinia- 
infected fibroblast targets sharing other HLA class I  alleles 
with  IM59  and  IM52  did not  reveal any  additional EBV 
antigen-specific reactivities, suggesting that in both of these 
patients a  single latent protein was  the dominant  target of 
the primary CTL response. 
With IM53  (HLA A3, A30, B8, B18), it was possible to 
carry  out  the  recombinant  vaccinia  assays  on  autologous 
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Figure 2.  Screening  of  in vitro expanded IM primary effectors for anti- 
gen-speclfiC reactlvmes (left) and epltope-speclfic reactlwtles (right) using 
targets as described m Fig. 1. Results are expressed as percentage of spe- 
ofic lysls in 5-7-h chromium release assays for (A) IM59 effectors, (B) 
IM52 effectors, and (C) IM53 effectors tested at E/T ratios of 10:1 (11) 
and 5:1 ([]). 
target cells  because, in contrast to IM59 and IM52, lysis  of 
the  autologous spontaneous  LCL by primary IM53  effec- 
tors was unusually low. These assays again revealed prefer- 
ential  reactivity  against  one  immunodominant  latent  pro- 
tein, in this case EBNA3A (Fig.  1 C-). These same effectors 
were  therefore  screened  against  the  relevant  EBNA3A- 
derived  peptides  known  to  be  epitopes  for A3-restricted 
memory (EBNA3A 603-611, ref. 24) and for B8-restricted 
memory (158-166 and 325-333), respectively. Strong reac- 
tivity was  detected  against  one  of these  peptides,  the  B8- 
restricted epitope EBNA3A 325-333 (Fig.  1 C). 
Analysis of In  Vitro Expanded  Polyclonal Primary  Effectors. 
It was possible to expand IM effector cell numbers in short- 
term  culture  by  cocultivating  with  irradiated  cells  of the 
autologous  spontaneous  LCL  in  IL-2-conditioned  me- 
dium; this generated effector populations that could be an- 
alyzed in greater detail, as exemplified by the data in Fig. 2. 
For IM59, in vitro expanded effectors again showed reac- 
tivity only against EBNA3A when tested on A2, B8-matched 
fibroblasts,  and  peptide  assays  confirmed  the  presence  of 
,  reactivities  against  both  of  the  B8-restricted  EBNA3A 
epitopes,  158-166  and  325-333  (Fig.  2  A).  In the  case  of 
IM52,  the  in vitro  expanded  effectors not only contained 
the dominant All-restricted reactivity to EBNA3B 416-424 
that had been detectable  in ex vivo assays,  but it was now 
possible to detect subdominant reactivities against the other 
known All-restricted  epitope in EBNA3B,  399-408,  and 
against  the  known  B35-restricted  epitope  in  EBNA3A, 
458-466  (Fig. 2  B).  Further assays did not reveal any latent 
antigen-specific lysis mediated through the other HLA class 
I  alleles  of IM59  or IM52  (data not shown).  The in vitro 
expanded effectors from IM53 resembled the ex vivo pop- 
ulation  in  that  reactivity  was  focused  entirely  against  the 
EBNA3A antigen.  However, we noted that there must be 
more  than  one  component of this  EBNA3A-specific lysis 
because in recombinant vaccinia assays it was detectable  on 
A3-matched as well as on B8-matched fibroblasts (Fig. 2  C 
and  data  not  shown).  Analysis of these  in  vitro  expanded 
effectors on peptide-loaded  targets confirmed the presence 
of a major response against the EBNA3A 325-333 epitope, 
already seen in the ex vivo assays with  IM53, and also re- 
vealed additional  reactivities  against the second B8-restricted 
epitope  EBNA3A  158-166  and  against  the  A3-restricted 
epitope  EBNA3A  603-611  (Fig.  2  C),  neither  of which 
had been detectable immediately ex vivo. 
Analysis of Primary CTL Clones.  As  a  first  approach  to 
analysis at the clonal level, IM mononuclear cells were seeded 
immediately  ex vivo at  0.3-300  cells/well in  IL-2-condl- 
tioned medium with irradiated autologous LCL cell stimu- 
lators and irradiated pooled allogeneic lyrnphocytes as feeders. 
Using this protocol, we regularly observed successful T  cell 
outgrowth from almost all wells with a 300-cell input, from 
>50% of wells seeded at 30 cells/well,  from up to  10% of 
wells seeded at 3 cells/well,  and even from occasional wells 
seeded at an average of 0.3 cells/well.  Screening in recom- 
binant vaccinia and/or peptide sensitization assays gave evi- 
dence  of  EBV-specific  cytotoxicity  in  >90%  of  wells 
growing from a 300-cell input,  in 30-70% of wells grow- 
ing from a 30-cell input,  and in  10-50% of wells growing 
from lower cell seedlngs.  Moreover,  the  relative  yields  of 
CTL  specific  for  different  epitopes  were  consistent  with 
their  relative  frequencies  in  the  original  IM mononuclear 
cell population,  at  least  as  reflected  in  the  ex vivo  assays. 
For example,  the  dominant reactivity shown by IM52  ef- 
fectors ex vivo had been against the All-restricted epitope 
EBNA3B 416-424, and indeed two of eight wells giving T 
cell outgrowth from an initial 3-cell input contained effec- 
tots with this particular specificity (e.g.,  culture c13, Fig. 3 A), 
as did many of the wells growing from higher inputs (Fig. 3 
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Figure  3.  Cytotoxlcity testing of in vxtro expanded T  cell populations 
established from low cell seechngs of IM52  mononudear  cells.  Epltope- 
specific reactlvmes were detected using autologous PHA blast targets pre- 
exposed to the denoted epltope pepndes at 1  lxg/ml or to an equivalent 
dilution of DMSO  solvent (no-peptide control). 1Lesults are expressed as 
percentage of specific lysls m  a 5-h chromium release assay at an E/T  ratio 
of 5.1  for (A)  c13 effectors expanded from an initial seeding of 3  cells/ 
well,  and for  (B)  c154 effectors and  (C)  clll  effectors,  both  expanded 
from an mltlal seeding of 300 cells/well.  In  this experiment,  8/96 wells 
seeded  at  3  IM52  mononuclear  cells/well  gave  T  cell  outgrowth,  of 
which  2  showed  EBV  specificity, both  recognizing the  EBNA3B  416- 
424 epltope,  and 96/96  wells  seeded at 300 cells/well  gave T  cell out- 
growth,  of which  85  recognized the  EBNA3B  416-424  epltope  (m  76 
cases as the only reactivity and m  3  and 6  cases, respecnvely, alongside re- 
activity against the other two epltopes),  4  recognized the EBNA3B  399- 
408  epitope  (m  1  case  as  the  only  reactivity  and  3  cases  alongside 
EBNA3B  416-424 reacUvlty), and 8  recognized the  EBNA3A  458-466 
epltope  (in  2  cases  as  the  only  reactivity  and  in  6  cases  alongside  the 
EBNA3B  416-424 reactivity). 
legend).  Other less abundant IM52 reactivities, against the 
second All-restricted epitope EBNA3B 399-408 and against 
the  B35-restricted  epitope EBNA3A 458-466,  were  only 
detectable  in  some  of the  wells  growing  from a  300-cell 
input  (e.g.,  cultures  c154  and  c446,  Fig.  3,  B  and  C).  In 
subsequent  experiments,  we  showed  that  primary  CTL 
growth from such limiting dilution cultures required both 
the immediate provision of IL-2 and the presence of LCL 
stimulators expressing the relevant cognate antigen. For in- 
stance, in the  case  of IM52,  we compared the stimulatory 
capacity of two LCLs from the same All-matched donor, 
one carrying a viral genome encoding both of the relevant 
All  epitopes,  the  other  carrying a  viral variant  (29)  that 
lacks the immunodominant EBNA3B 416-424 epitope; only 
the  former produced  efficient  clonal  outgrowth  of IM52 
CTL specific for EBNA3B 416-424 (data not shown). 
More  detailed  dissection  of the  primary CTL response 
was subsequently achieved by cloning at 0.3  cells/well ei- 
ther from oligoclonal cultures of the kind described above 
or  from  the  short-term  polyclonal  lines  described  in  the 
previous section. Representative results are shown in Fig. 4 
from the clonal analysis  of IM53 effectors; the data indicate 
that this patient's dominant EBNA3A reactivity in fact con- 
tained four separate components. Note that in the first set 
of experiments  only  one  of the  three  known  EBNA3A- 
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A.  IM53  c28  effectors 
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40 
30 
20 
10 
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Figure  4.  Cytotoxlclty testing of IM53-denved pnmary T  cell clones 
for  EBNA3A  epltope-speclfic  reactivmes.  T  cells  were  assayed against 
HLA class l-matched targets, either uninfected or expressing EBNA3A or 
LMP2  from recombinant vacclma vectors, and against autologous PHA 
blasts preexposed to the  denoted EBNA3A  epttope peptides at  1  I~g/ml 
or to an equivalent &lution of DMSO  solvent (no-peptide control). 1Le- 
sults are expressed as percentage of specific lysls m  a 5-h chromium release 
assay at an E/T  rano of 5:1  for (A)  c28,  (B)  c68, and (D)  c24, all estab- 
lished  from  limiting  dilution  cloning  of an  m  vitro  expanded  pnmary 
CTL  line,  and  (C)  c44,  estabhshed  from  a  low  cell  seeding  of IM53 
mononuclear cells. Table  1.  Summary  of Detectable Primary and Memory CTL Reactivities 
Panent  HLA allele  EBV antigen  EBV epitope*  Primary response  Memory response 
IM50  A 11  EBNA3B  399-408  +:~  + ~: 
A23  LMP2  131-140  +  + 
B49  n.t. 
B60  LMP2  200-208  +  + 
IM52  All  EBNA3B  399-408, 416-424  +,  +*  +,  +* 
A30  - 
B13 
B35  EBNA3A  458-466  +  + 
IM53  A3  EBNA3A  603-611  +  Undetectable 
A30  EBNA3A  176-184  +  + 
B8  EBNA3A  158-166, 325-333  +,  +*  +,  +* 
B18 
IM59  A1 
A2 
B8  EBNA3A  158-166, 325-333  +*,  +  +,  + 
B62 
IM63  A1 
A2 
B8  EBNA3A  158-166, 325-333  +,  +*  +,  +* 
B49  n.t. 
IM66  All  EBNA3B  399-408, 416-424  +,  +  +,  + 
A28  n.t. 
B18 
B35  EBNA3A  458-466  +~  +* 
IM54  A2 
A3 
B14 
B44  EBNA3C  ?  +*  +5 
IM57  All  EBNA3B  399-408,  416-424  +,  +*  n.t. 
A32  n.t. 
B35  EBNA3B  458-466  +  n.t. 
B61  n.t. 
IM61  A2 
A3  EBNA3A  603-611  +  n.t. 
B7  EBNA3A  379-387  +  n.t. 
B44  EBNA3C  281-290  +  n.t. 
IM69  A2 
A32 
B7  EBNA3A  379-387  +*  n.t. 
EBNA3C  881-891  +  n.t. 
B63  rt_t. 
*Epitopes were defined in previous studies on memory CTL response (15-18) with the exception of the B60-restncted LMP2 200-208 (Lee, S.P., 
R.J. Tierney, W.A. Thomas, J.M. Brooks, A.B. P,.ickmson, manuscript submitted for pubhcanon) and the A30-restricted EBNA3A 176-184 epitope 
(this study). Note that in the case of IM54, the B44-restricted EBNA3C-speclfiC response was not defined at the epltope level. 
*Denotes the lmmunodominant reacttvity as judged from polyclonal CTL hnes and clones. 
n t, not tested. 
1806  Primary CTL Responses to EBV derived  CTL  epitopes,  325-333,  was  recognized  by  the 
IM53  effector preparation  in  ex  vivo  assays  (Fig.  1  C). 
However,  this particular reactivity was unlikely to be re- 
sponsible for the lysis ofvacc-EBNA3A-infected targets by 
these same effectors (Fig.  1 C) because this vacclnia recom- 
binant carries the B95.8 strain EBNA3A sequence in which 
the 325-333  epitope is lost  (30).  By way of confirmation, 
all  of the limiting dilution  clones from IM53  that recog- 
nized  the  EBNA3A  325-333  peptide  failed  to  recognize 
HLA-B8-positive targets expressing B95.8 EBNA3A from 
the recombinant vaccinia (e.g., c28; Fig. 4 A). In contrast, the 
smaller number of IM53-derived clones that mapped to the 
other B8-restricted EBNA3A epitope 158-166 or to the A3- 
restricted  EBNA3A  epitope  603-611  did  recognize  the 
vacc-encoded EBNA3A  (e.g.,  c68  and  c44,  respectively; 
Fig. 4,  B and  C).  In addition, we found another relatively 
abundant  set  of  IM53  clones  that  were  specific  for 
EBNA3A in vaccmia assays but that did not recognize any 
of the three previously defined peptide epitopes. Such clones, 
represented by c24 in Fig. 4 D, were found to be restricted 
through a different blLA class I allele, HLA-A30, and were 
mapped  in  peptide  screening  assays  to  a  new  epitope, 
EBNA3A  sequence  residues  176-184  (sequence  AYSS- 
WMYSY). 
Summary  of EBV-specific Reactivities Detectable in  IM Pa- 
tients.  A  ¢otl  of 40  IM  patients  were  analyzed by the 
methods i~urstraced in Figs. 1-4, and the EBV-specific CTL 
reactivities detectable in the blood of each patient are sum- 
marized  in  Table  1.  In  each  case,  the  primary CTL  re- 
sponse was focused on one or two target antigens only and, 
despite the variety of the patients' HLA types, these target 
antigens were almost always drawn from the EBNA3A, 3B, 
3C family. In fact, even after in vitro expansion of the re- 
sponse and testing on a range of HLA class I-matched tar- 
gets,  only one patient showed evidence  of reactivity out- 
side the EBNA3A, 3B, 3C family; this was IM50, in whom 
an EBNA3B-specific response was accompanied by weaker 
reactivities against LMP2.  The antigen specificity of these 
pnmary  CTL  was  in  almost  every case  confirmed  at  the 
peptide  level,  and  frequently  the  effectors were  found  to 
recognize peptides already known to be target epitopes for 
memory responses in healthy donors (Table 1).  For exam- 
ple, all three HLA-B8-positive patients tested (IM53, IM59, 
and  IM63)  generated primary responses  to  the  EBNA3A 
158-166  and  325-333  epitopes.  Likewise,  of  the  four 
HLA-A11-positive patients tested, three (IM52, IM57, and 
IM66)  generated primary responses to the EBNA3B  399- 
408  and 416-424  epitopes. The fourth patient,  IM50, was 
particularly interesting in that here A11-restricted EBNA3B- 
specific effectors again formed the dominant component of 
the  primary  response  yet  were  focused  against  399-408, 
usually the "weaker" of the two All  epitopes, with no re- 
activity detectable against 416-424. Sequencing of the EBV 
strain present in the  IM50 spontaneous LCL subsequently 
identified  this as one of the rare Caucasian isolates with a 
lysine-to-asparagine mutation at EBNA3B position 424, an 
anchor residue change that effectively destroys antigenicity 
of the immunodominant 416-424 epitope (29). 
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Comparison of Primary and Memory CTL Reactivities in In- 
dividual Patients.  Several of these patients were resarnpled 
on  a  number  of occasions between  6  mo  and  2  yr after 
their clinical recovery from IM; each time, memory CTL 
preparations  were  generated by in  vitro  stimulation  with 
the same autologous LCL as had been used to analyze the 
primary response. The results of this work are summarized 
for individual patients in Table 1, and representative assays 
on  polyclonal  memory  CTL  preparations  from  post-IM 
donors  IM59,  IM52,  and  IM53  are  illustrated  in  Fig.  5. 
The memory CTL response in IM59 resembled that seen in 
primary  infection  in  that  EBNA3A-specific,  HLA-B8- 
restricted lysis was the only detectable reactivity on recom- 
binant vaccinia-infected fibroblasts  matched through a vari- 
ety of HLA-A and -B alleles  (data not shown). Subsequent 
assays on peptide-loaded targets showed that both compo- 
nents  of the EBNA3A-specific response detected in acute 
IM,  namely,  against  the  158-166  and  325-333  epitopes, 
were  also  present  in  memory (Fig.  5  A).  Likewise poly- 
clonal  memory  CTL  preparations  from  IM52  contained 
EBNA3A- and EBNA3B-specific components as the only 
detectable EBV reactivities (data not shown),  and all three 
epitope  specificities  that had been seen in  the  primary re- 
sponse, against the two All-restricted epitopes in EBNA3B 
and against the B35-restricted  epitope in EBNA3A,  were 
again detectable in memory (Fig.  5 B). Primary and mem- 
ory responses were not always concordant, however. Thus 
in vitro reactivated memory CTL from IM53 were found 
to  be  exclusively EBNA3A  specific  in  recombinant vac- 
cinia assays (data not shown) and showed strong lysis of the 
two B8 epitopes (EBNA3A 158-166  and 325-333)  and of 
the newly described A30 epitope (EBNA3A 176-184)  that 
had been recognized by primary effectors from this patient 
(Fig.  5  C).  However,  another  target  of the  primary  re- 
sponse, the A3 epitope EBNA3A 603-611,  was never rec- 
ognized by any of the memory CTL preparations generated 
from this  individual  8,  16,  and  21  mo after resolution  of 
symptoms. 
The point was pursued more rigorously in a further se- 
ries  of experiments in  which  cryopreserved mononuclear 
cells from the acute IM53 bleed and from the same patient 
21  mo later were analyzed using exactly the same limiting 
dilution assay conditions, with the results shown in Fig.  6. 
We found that the B8-restricted EBNA3A 325-333  reac- 
tivity was the dominant component both in the primary re- 
sponse  and  in  memory,  mean  frequencies  being,  respec- 
tively,  1/144  and  1/2,684  of the  circulating mononuclear 
cell population at those times (Fig.  6 A);  these recalculate 
to frequencies within the circulating CD8 ÷ T  cell popula- 
tion of 1/93 during acute IM and 1/733  during long-term 
virus  carriage  (see  Table 2).  By comparison,  CTL to  the 
second B8 epitope were less numerous both during the pri- 
mary response (1/5,196)  and in memory (1/18,876);  how- 
ever,  the  extent  to which  this  CTL frequency had fallen 
between the two phases of infection was much less marked 
than for CTL to the dominant epitope (Fig. 6 B and Table 2). 
In the  same expenments,  limiting dilution  analysis  of the 
A3-restricted EBNA3A 603-611--specific response showed A.  IM59  in vitro re-activated  memory  effectors 
_•60- 
[  A2epitopes  l}  B8epitopes  [ 
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°~  aut 
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C.  IM53 in vitro re-activated memory effectors 
AB  B8  A30 
70-1  [epitopell  epltopes  II eptt°Pe[ 
3O- 
20- 
10- 
0 
aut  "~  <  "  <  "  <  6  <o6 
LCL  K  Z~  Z~  mX~  ~r- 
I  I 
aut~logous  PHA blasts + peptide 
Figure  5.  Screening of in vitro reactivated memory CTL preparations 
from  post  convalescent  IM  donors.  EBV-speclfic  reactlvltles were  de- 
tected  using  autologous  PHA  blast  targets  preexposed  to  the  denoted 
epitope peptldes at 2  p.g/ml (A and C) or 0 2  txg/ml (B) or an equivalent 
ddutlon of DMSO  solvent (no-peptide control). Results are expressed as 
percentage of specific lysls in a 5-h ehrormum release assay using memory 
CTL  from  (A)  post-IM  donor 59,  (/3) post-IM donor 52,  and  (C)  post- 
IM donor 53 at E/T  ranos of 10.1  (m) and 5:1  (~). Levels oflysls of the 
autologous spontaneous LCL target in the same assays are also shown for 
reference. 
A. 
1120- 
50- 
25 
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o 
-  -  -o  ............... 
o 
5000  10000 
input cells  / well 
B° 
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~  25- 
~  12- 
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3- 
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EBNA 3A 158-166 -spectfic CTLs 
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input  cells / well 
C.  EBNA 3A 603-611 -specific  CTLs 
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Figure  6.  Limiting &luuon analysis of primary (4')  and memory (~) 
CTL m CD 16-depeleted mononuclear cell preparanons from IM53 taken 
m the acute phase of'the disease and after 21  too, respectively. Sets ofrep- 
hcate ohgoclonal cultures (n  =  24),  derived from wells seeded with  m- 
creasing cell input numbers, were screened agamst autologous PHA blast 
targets preexposed to the denoted epltope peptldes at  1 p,g/ml  At each 
cell input number, results for each epltope were expressed as the percent- 
age of wells negative for recognmon of the epxtope. The epltope-speofic 
CTL frequency was then calculated by the method of maxamum hkeh- 
hood and is shown on the graph as the point at which 37% of wells are 
negative; 95% confidence hlmts at this point are as shown (shaded area). 
Data  for  CTL  specific  for  (A)  the  EBNA3A  325-333  epitope  (B8  re- 
stncted)  calculated  from  stimulation  with  the  autologous  spontaneous 
LCL,  (/3) the  EBNA3A  158-166  epltope  (B8  restricted),  and  (C)  the 
EBNA3A 603-611  epltope (A3 resmcted), both calculated from stmmla- 
tlon with the autologous LCL carrying the B95.8 viral strain, which lacks 
the immunodommant EBNA3A 325-333 epltope. Note the &fference in 
scale of input cells per well m  (A) versus (B) and (C). 
these effectors to be relatively abundant  during  the primary 
response (mean frequency 1/3,086 mononuclear cells, equiva- 
lent to  1/1,998  CD8 + T  cells)  but undetectable  in memory 
(Fig.  6  C). 
Similar quantitative  studies  on IM52  and IM59  (see Ta- 
ble  2)  showed  that  effector  cells  specific  for  the  most  im- 
munodominant  EBV  epitope  (EBNA3B  416-424  for IM52, 
EBNA3A  158-166  for IM59)  again  constituted  at least  1% 
of the  circulating  CD8 +  T  cell  pool during  the  acute  pri- 
mary  infection.  The  other  subdominant  reactivines  were 
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 present at  15-20-fold lower frequencies in  IM52 and at a 
roughly  fourfold  lower  frequency  in  IM59.  Prospective 
analysis  of IM52 showed that,  as in the primary response, 
CTL specific for the EBNA3B  416-424  epitope remained 
the  most abundant  component  of memory, but  now the 
other reactivities were detectable at only 1.5-3-fold lower 
frequencies (Table 2).  Although precise memory CTL fre- 
quencies could not be obtained from the analysis  of IM59 
after convalescence,  the  pattern  of results  again suggested 
that differences in the relative frequencies of CTL to im- 
munodominant versus subdominant  epitopes were gener- 
ally less marked in memory than they had been during the 
primary response. 
Discussion 
The combined work of several laboratories has produced 
a quite  detailed picture  of EBV-specific CTL surveillance 
in  healthy  carriers,  and  has  shown  a  marked  skewing  of 
memory responses towards EBNA3A,  3B,  and 3C  (at  the 
expense of the other five latent proteins) in almost all indi- 
viduals analyzed (12-14,  31).  Although preferential target- 
ing of particular viral antigens has also been observed in the 
memory CTL response to another herpesvirus, cytomega- 
lovirus  (32-34),  there  it appears to  reflect the  differential 
immunogenicity of cells at a very early point in the infec- 
tious cycle before a virus-induced impairment of the antigen- 
processing pathway comes into play (35).  The heirarchy of 
immunodominance among EBV latent proteins cannot be 
explained in  such  a way because all  eight potential target 
antigens are coexpressed in the LCL-like latently infected 
B cell (11).  Such marked immunodominance is not seen in 
two  other  well-characterized  human  viral  systems,  influ- 
enza and HIV1, where memory CTL responses tend to be 
diversified across a wider range of the available target pro- 
teins  (36-38).  However, it is worth recalling the  different 
biologies of these agents because, in contrast to EBV, influ- 
enza does not establish persistent infection whereas HIV1 is 
a persistent  virus  but,  because  of its  genetic  instability,  is 
continually  generating  new  CTL  target  epitopes  in  vivo 
(39). Part of the impetus for the present work was therefore 
to  ask  whether  the  immunodominance  of the  EBNA3 
proteins and their derived peptides in EBV-induced  CTL 
memory was a product of long-term stable antigemc chal- 
lenge, with memory becoming progressively more focused 
over time.  Our findings indicate  that this is not the  case 
because  CTL  reactivities  are  highly  skewed  toward  the 
EBNA3  proteins and  their derived peptide  epitopes even 
during the acute primary infection. 
The antigenic specificities detectable in the primary CTL 
response  are  summarized for  10  IM patients  in  Table  1. 
Note that all the work was carried out using cryopreserved 
effector preparations, and it is of course possible that some 
less-abundant reactivities might have been lost during cry- 
ostorage and resuscitation.  However, there is no reason to 
believe  that  such  losses  would  alter  the  range  of more 
abundant responses detected.  It is therefore significant that, 
for all  10 patients studied, the ex vivo assays identified just 
one or two  dominant reactivities;  these  regularly mapped 
to  antigens  within  the EBNA3A,  3B,  and  3C  subset  and 
frequently to peptide epitopes already known to be immu- 
nodominant targets for memory responses in healthy virus 
carriers  (see  Fig.  1).  Short-term in vitro expansion of the 
IM T cell populations in IL-2 frequently revealed additional 
subdominant reactivities,  again usually directed against known 
EBNA3-derived epitopes (see Fig. 2). The presence of such 
additional reactivities during the acute phase of the disease 
clearly marks them as components of the primary CTL re- 
sponse, and the fact that they were not directly detectable 
in  ex vivo assays very probably reflects their lower abun- 
dance in the  IM T  cell pool.  The alternative explanation, 
that  these  particular  CTL  had  already  differentiated  to  a 
resting  "memory"  phenotype,  seems  inherently  unlikely 
because in previous work IM T  cell populations have been 
screened for EBV-speciflc memory in the conventional in 
vitro regression assay with uniformly negative results (40). 
An unexpected feature of these in vivo-activated EBV- 
specific effectors was the efficiency with which they could be 
expanded as clones from limiting dilution cultures (Fig. 3). We 
had not anticipated such efficient outgrowth given that acti- 
vated CD8 + IM T  cells are known to display a Fas(CD95)- 
positive,  Bcl2-negative  phenotype  characteristic  of  cells 
susceptible to apoptosis (41-43).  Indeed IM T  cells  do  die 
rapidly by apoptosis in vitro unless rescued by the immedi- 
ate provision  of IL2  (42-45),  and  even then  the  rescued 
cells  are reportedly susceptible to  "activation-induced  cell 
death" upon anu-CD3 ligation of the TCR complex (46). 
Though anti-CD3 mAb treatment has often been used as a 
surrogate for antigen-specific stimulation in in vitro T  cell 
cloning experiments (47,  48), we found this to be much in- 
ferior to  LCL stimulation  as  a  means  of cloning  primary 
EBV-specific effectors (data not shown). We infer that the 
autologous LCL is a very effective stimulus in our particu- 
lar system for two reasons: first,  it can deliver an epitope- 
specific signal through the TC1L, and this is clearly impor- 
tant because LCL expression of the cognate HLA-peptide 
complex was  essential  for  optimal  stimulation;  second,  it 
can deliver a costimulatory signal through the CD28 path- 
way because LCL cells  express high levels of the relevant 
ligands, CD80 and CD86 (49). 
The ex vivo cytotoxicity assays (Fig.  1) and in vitro lim- 
iting dilution assays (Figs. 3-5) conducted on individual pa- 
tients  gave  concordant  results  in  that  both  identified  the 
same  epitope-speclfic  reactivity as  immunodominant.  In- 
deed,  by limiting dilution,  CTL with  the  immunodomi- 
nant reactivity typically accounted for at least 1% of the cir- 
culating CD8 + pool (Table 2).  It is interesting to compare 
these figures with  those  from a recent collaborative study 
carried out on a different group of IM patients,  in which 
we  found  marked  expansions  of particular  V[3  subsets, 
which  frequently  accounted  for  >10%  of the  circulating 
CD8 +  T  cell  population  and  contained  marked  oligo- 
clonality  of TC1L  rearrangements  suggestive  of antigen- 
driven proliferation (50).  The present work may therefore 
be  underestimating  the  true  frequency of latent  antigen- 
specific CTL in  IM blood if,  for instance,  some of these 
1810  Primary CTL Responses to EBV primary effectors have terminally differentiated in vivo to a 
point where they are no longer responsive to in vitro stim- 
ulation;  the  fact that a proportion  of activated  CD8 +  IM 
T  cells have lost CD28  expression  (46)  would support  this 
possibility.  We should,  however,  stress that there are likely 
to  be  many  other  CD8 ÷  T  cell specificities  present  in  IM 
blood  alongside  the  EBV  latent  antigen-specific  response. 
Some  of these  may also  be  directly  EBV  induced  and  di- 
rected against virus lyric cycle antigens (51), whereas others 
could well be non-EBV-related specificities  (20, 21), which, 
as a result of local  cytokine production,  have been  coinci- 
dentally  expanded  in  vivo  alongside  the  virus-specific  re- 
sponse  (9). 
The  ability  to  expand  and  clone  primary  EBV-specific 
effectors  in  vitro  is  important  in  a  number  of contexts. 
First,  it  allows  a  much  more  precise  dissection  of the  pri- 
mary response  into its  constituent  reactivities,  as illustrated 
here for IM53  (Fig. 4).  Second, it makes possible a detailed 
comparison  of primary  versus  memory  responses  in  the 
same individual  (Figs. 2, 5, and 6). Our experiments to date 
show that in most cases the  range  of reactivities  detectable 
in  memory  (at least up  to  2  yr after infection)  reflects  the 
range present in the primary response,  in such cases there is 
a  fall  in  CTL  frequencies  between  the  two  phases  of the 
infection;  however,  the  reactivity  that  was most  abundant 
in  the  primary  response  appears  to  be  disproportionately 
culled  so  that  its  numerical  dominance  over  subdominant 
reactivities  is  much  less  marked  in  memory  than  it  was 
during  the  primary  infection.  This  may  reflect  either  the 
exhaustion  of particular clones responding to the immuno- 
dominant epitope (52) or some other homeostatic mechanism 
regulating clonal dominance within immune responses. Per- 
haps  the most interesting aspect of such  comparative  stud- 
ies,  however,  was  the  identification  in  one  patient,  IM53, 
of an  A3-restricted  reactivity,  which  formed  a  significant 
component  of  the  primary  response  (1/1,998  CD8 +  T 
cells) but, using the same stimulation protocol  and stimula- 
tor LCL, was consistently undetectable in memory (Fig. 6). 
It is  not  clear what  underlies  this  selective loss  of the  A3- 
restricted response but it seems unlikely to be the result of 
clonal  exhaustion  per se because the primary A3-restricted 
effectors could be expanded in vitro as efficiently as coresi- 
dent effectors against the other epitopes. The result suggests 
that  the  mere  presence  of a  reactivity  in  the  primary  re- 
sponse  does  not  guarantee  its  representation  in  memory 
and  that  the  culling process  to  which  all primary effectors 
are subject  may in some  circumstances  eliminate particular 
reactivities. 
Taken overall,  our findings represent the first unequivo- 
cal demonstration of an EBV-specific CD8 ÷ CTL response 
in IM; the only other well-documented report of lM T  cell 
specificity  describes  an  unusual  HLA class  II-restricted  re- 
sponse  to  an  EBV  lytic  cycle  antigen  (53).  The  most  im- 
portant  conclusion  from  our  work  is  that  the  focusing  of 
EBV-induced  CTL responses on the EBNA3  proteins  and 
their derived peptides is as marked during primary infection 
as it is during long-term virus carriage. This strengthens the 
notion  that  these  particular  antigens  may be  in  some  way 
more  accessible  to  the  HLA  class  I-processing  pathway 
,  than  other EBV  latent proteins  although,  with  the  excep- 
tion of the EBNA1  protein  (54),  the basis of such differen- 
tial accessibility is at present not understood.  However, the 
work also emphasizes that the precise composition  of CTL 
memory  in  the  EBV  system  is  not  simply  a  scaled-down 
version of the primary response,  indicating that other selec- 
tive factors may influence the content of the memory pool. 
Complete loss of an epitope-specific reactivity would be an 
extreme  example  of this  selective  process,  and  perhaps  a 
more common example might be selection operating within 
an epitope-specific response at the level of individual TCR 
usage  (55).  Further studies will be required to examine this 
latter  possibility  but,  if such  selection  did  occur,  it  might 
help to explain the extremely limited range of TCRs found 
in certain EBV epitope-specific memory populations  (56). 
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